BESPONSA Injection 1 mg Special Investigation

BESPONSA® INJECTION 1 MG SPECIAL INVESTIGATION

The purpose of this study is to learn about the safety and effectiveness of BESPONSA. BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia.

Registration criteria for this study is all patients who starting BESPONSA in Japan from its launch to the market to April 30, 2020.

All patients in this study will receive BESPONSA according to the prescriptions.

Patients will be followed up as follow.

• 52 weeks for patients who did not have a HSCT (Hematopoietic Stem Cell Transplant) within 52 weeks after starting BESPONSA.
• Up to 52 weeks after a HSCT for patients who had a HSCT within 52 weeks after starting BESPONSA.

Inclusion Criteria:

• All patients prescribed BESPONSA

Exclusion Criteria:

• None